Introduction {#S1}
============

Obstructive sleep apnoea-hypopnoea (OSAH) is characterised by repeated interruption of breathing during sleep due to episodic collapse of the pharyngeal airway. These episodes usually cause oxygen desaturation and are terminated by micro-arousals from sleep. This sleep disruption commonly causes excessive daytime sleepiness (EDS) \[[@R1]\].

Published studies suggest that OSAH affects 2%--7% of the adult population \[[@R2]\]. It becomes more prevalent in middle age and males have approximately double the risk of developing the condition \[[@R3]\]. The main modifiable risk factor for OSAH is obesity, particularly when adiposity is distributed around the neck and upper body \[[@R4]\]. Others include smoking and alcohol use. Medical conditions such as hypothyroidism, polycystic ovary syndrome and acromegaly have also been associated with OSAH \[[@R2],[@R4]\].

The sequelae of OSAH can be serious. There is a causal link with hypertension \[[@R5]\]. A recent meta-analysis estimated the risk of cardiovascular disease (CVD) to be 2.5 times higher in patients with moderate-severe OSAH \[[@R6]\]. This association is supported by biologically plausible mechanisms. Intermittent hypoxia, micro-arousals and excessive negative intrathoracic pressure swings may all play a role, mediated via sympathetic activation, oxidative stress and inflammation, as well as through direct cardiac effects \[[@R7]\]. There is also evidence for improvement in cardiovascular outcomes when OSA is treated. While the case is strongest for hypertension, there may be other cardiovascular benefits, although conclusive evidence is still needed. There are other consequences of OSAH. Impaired vigilance is responsible for a two to three fold increase in road traffic accident (RTA) risk \[[@R8]\], while health related quality of life (HRQoL) is also diminished \[[@R9]\]. Healthcare usage is almost doubled in OSAH, with one of the main determinants of increased cost being CVD \[[@R10]\].

The AHI is an objective, sensitive and specific measure of the severity of OSAH. It allows useful if arbitrary disease categorisation, although differing hypopnoea definitions introduce variability. The American Academy of Sleep Medicine (AASM) defines mild OSAH as an AHI of 5--14 events per hour; moderate OSAH as 15--30 events per hour; and severe OSAH as an AHI of greater than 30 events per hour \[[@R11]\].

Impact on excessive daytime sleepiness (EDS) is routinely measured when evaluating the effectiveness of different treatments for OSAH. The extensively validated Epworth sleepiness scale (ESS) is the most frequently used instrument \[[@R12]\]. As a subjective measure it is susceptible to significant placebo effects \[[@R13]\] but it has been found to be the best among a range of validated outcome measures in predicting real response to OSAH treatment \[[@R14]\].

For milder cases of OSAH, treatment focuses on lifestyle modification (weight loss, smoking cessation, reduction of alcohol intake, position management and sleep hygiene). When the symptoms of OSAH are more severe definitive treatment is usually recommended, most commonly CPAP. Pressure generated by an electric air pump is applied to the upper airway via a face mask. It provides a pneumatic splint which maintains pharyngeal patency during sleep. There is good evidence that CPAP reduces obstructive events and improves daytime sleepiness, cognitive function, HRQoL and CVD risk factors. However almost all trials have been conducted in patients with moderate-severe OSAH \[[@R9],[@R15],[@R16]\], and CPAP intolerance, which frequently undermines its effectiveness, may be a particular problem in milder disease \[[@R17]\].

Mandibular advancement devices (MAD) are an alternative to CPAP in the treatment of OSAH. Worn intraorally during sleep, they can prevent upper airway collapse by holding the mandible and tongue forward. A wide variety of devices are available, covering a range of sophistication and cost. Improvement in respiratory events has been associated with MAD-mediated increase in upper airway dimensions \[[@R18]\]. The positive treatment effect, coupled with compliance rates that may be higher than for CPAP, suggest MADs are an effective treatment in patients with mild to moderate OSAH.

Three meta-analyses have examined the evidence for the use of MAD in OSAH \[[@R9],[@R15],[@R19]\]. Lim et al. \[[@R19]\] reviewed 17 RCTs on MAD involving 831 patients. They concluded that MADs were effective in reducing AHI, ESS and other measures of sleep-disordered breathing compared with conservative management (CM), but less than CPAP. Effects on quality of life, symptoms, CVD risk factors and RTAs were unclear due to the small number of studies and inconsistent methodology. An earlier Cochrane review \[[@R15]\] compared CPAP to controls and MADs in separate analyses. CPAP was best at reducing AHI. However, ESS improvements were similar for CPAP and MADs, with both better than no treatment. There was evidence of greater CPAP effectiveness with increasing baseline AHI severity. McDaid et al. \[[@R9]\] compared CPAP with control (placebo and conservative treatment) and MAD in separate analyses. They identified 48 studies reporting at least one measure of clinical effectiveness. Twenty-nine included ESS as the primary outcome. Most studies included people with severe disease by baseline AHI. There was less evidence of a difference between CPAP and MAD impacts on ESS, compared to CPAP and control. The small number of trials directly comparing these two treatments makes it difficult to elucidate the reasons for the differing AHI and ESS effects, but others have also noted only moderate correlation between AHI and ESS \[[@R20]\]. In common with Lim et al., \[[@R19]\] results regarding quality of life and cardiovascular risks were inconclusive due to the small numbers of trials and patients, short follow up and heterogeneous outcome measures.

This meta-analysis was designed to update systematic reviews of the effects on OSAH of MAD and CPAP, compared with each other and with CM, and to estimate the effect on AHI and ESS of both treatments. This includes assessment of heterogeneity due to baseline AHI severity, baseline ESS severity, trial methodology and duration of follow up.

Methods {#S2}
=======

Search strategy for the systematic review {#S3}
-----------------------------------------

The systematic review included RCTs of adult (16 y or older) OSAH patients with at least one arm randomised to MAD or CPAP. Exclusions were: studies comparing two different MAD or two different types of CPAP (differences within treatment modalities are small and numerous different devices are available), animal studies, non-randomised studies and trials published in a language other than English.

Information sources used to identify studies {#S4}
--------------------------------------------

The search strategy updated two existing systematic reviews \[[@R9],[@R19]\] to August 2013, when the main analysis was conducted. The main stages of the search are described below.

1.  All studies reported in the McDaid et al. systematic review \[[@R9]\] were included, which searched 14 databases up to November 2006 and included all RCTs of CPAP compared with either MAD or a non-MAD control. This search was repeated in 2012 by the authors of McDaid et al. (York University Centres for Reviews and Dissemination and for Health Economics) and results were shared with the authors of this article. This search strategy was repeated, by the authors, to retrieve articles from March 2012 to August 2013 using MEDLINE, Embase and the Science Citation Index, the three most sensitive databases reported by McDaid \[[@R9]\], to identify recent trials.

2.  The search by McDaid et al. \[[@R9]\] did not include studies of MAD against CM. Therefore additional papers were identified from Lim \[[@R19]\], and an updated version of the Lim strategy re-run to cover the period June 2008 and August 2013, using MEDLINE, Embase and the Science Citation Index.

3.  Reference lists of papers were searched and supplemented by the research team\'s expert knowledge of the area to identify other trials missed in updated searches.

Inclusion criteria {#S5}
------------------

All studies published by McDaid et al. and Lim et al. were reviewed. For subsequent searches, titles and abstracts were screened independently for relevance by two of the authors (of MB, MG, AC-J, RC and MP). Disagreements were resolved by consensus.

Patients {#S6}
--------

Full papers were retrieved for RCTs of adult patients with newly diagnosed or existing OSAH of any severity and confirmed using an appropriate method such as polysomnography. Studies were excluded if OSAH was not the predominant diagnosis, for example sleep disordered breathing associated with heart disease, stroke or dementia.

Interventions {#S7}
-------------

Trials with at least one randomised comparison of i) MAD (fixed or adjustable) against CM ii) CPAP (fixed or autotitrating) against CM, iii) MAD (fixed or adjustable) against CPAP (fixed or autotitrating) were included. CM included usual care, recommendation to lose weight or reduce alcohol consumption, sham device, placebo pill or postural device aimed at discouraging supine sleeping. Although data were extracted from studies where a surgical intervention was compared with either MAD or CPAP, this was not considered to be CM and the studies were excluded from the meta-analysis.

Trial methods {#S8}
-------------

All trial methodologies that included randomised allocation were included. In practice, trials were either i) crossover in design, with all patients receiving at least one active treatment and the order of treatment determined at random, or ii) individually-randomised, parallel-groups trials, with each patient receiving one treatment only. Trials in which the treatment duration was ≤ one week were excluded since this period was considered inadequate to produce a treatment effect.

Outcome measurements {#S9}
--------------------

This review focusses on AHI and ESS, the most commonly reported outcomes used to assess treatment effectiveness.

Data extracted from published studies {#S10}
-------------------------------------

For previously published reviews (see above), estimates of treatment effects recorded in the relevant papers were used after checking their accuracy in the published article or abstract \[[@R9],[@R19]\]. For newly identified studies information from full papers was extracted independently by two of the authors (of MB, MG, AC-J, RC and MP) and entered onto a bespoke data extraction form. Queries were resolved by consensus. Studies available as abstracts only were included provided that we could verify the inclusion and exclusion criteria, and at least one of the outcomes of interest was reported. For the updated review of MAD, if data in the published abstract, index paper, or a related publication were unclear, the authors were approached for further information. It was not possible within the timescale of the study to pursue authors of trials involving CPAP for data that were not published in the abstract, index paper, or a related publication.

Data extracted included details of the patient sample and baseline characteristics, intervention and comparator, outcome measurements, trial methodology, treatment duration and results.

Mean differences between the groups for continuous outcomes, and standard errors of the group differences, were extracted for the meta-analysis.

Quality assessment {#S11}
------------------

The Jadad score was calculated as a measure of quality for consistency with previously published reviews \[[@R9],[@R19]\]. The Jadad score was calculated by one reviewer and checked by a second.

Publication bias {#S12}
----------------

Funnel plots were examined as an informal method of assessing publication bias. These showed little evidence of asymmetry but the number of studies was too small for more formal analysis.

Data analysis {#S13}
-------------

Three separate meta-analyses were conducted, one for each of the comparisons i) MAD against CM, ii) MAD against CPAP and iii) CPAP against CM. Meta-analyses used random effects methods and were implemented using **metan** and related commands in STATA version 12 \[[@R21]\] and in WinBUGS \[[@R22]\]. In brief, this model was formulated as follows. From each study *i* we have an estimate of the treatment effect compared with the control treatment as ${\hat{\beta}}_{i}$ and we assume that these estimates follow a *Gaussian* distribution with $$\left. {\hat{\beta}}_{i} \middle| \beta_{i} \sim N\left( {\beta_{i},\sigma_{i}^{2}} \right) \right.$$ where *β*~*i*~ is the underlying mean treatment effect and $\sigma_{i}^{2}$ is the standard error in trial *i*. We assume that the trials are exchangeable *a priori* and that the underlying trial parameters *β*~*i*~ are drawn from a *Gaussian* distribution with mean *μ* = *E*\[*β*~*i*~\] and variance *τ*^2^ = *Var*\[*β*~*i*~\].

The methods used in STATA follow DerSimonian and Laird (1986) \[[@R21]\] who take a classical approach to random-effects metaanalysis. The expected treatment effect *μ* is estimated as the weighted average, $$\hat{\mu} = {\sum{{\hat{\beta_{i}}{\hat{w}}_{i}}/{\hat{w}}_{i}}}$$ where the weights are given by the inverse of the estimated total variance ${\hat{w}}_{i} = {1/{\left( {\sigma_{i}^{2} + \tau^{2}} \right).}}$

The standard error of $\hat{\mu}$ is approximated by $\sqrt{\left( {1/{\Sigma{\hat{w}}_{i}}} \right)}$ and an approximate 95% confidence interval is given by $$\hat{\mu} \pm 1.96\sqrt{\left( {1/{\Sigma{\hat{w}}_{i}}} \right)}.$$

All outcomes were assumed to be normally distributed. The standard error term $\sigma_{i}^{2}$ was estimated by the within-trial standard error. Where only 95% confidence intervals were available the standard error was estimated using (upper limit-lower limit)/3.92.

Although we investigated combining all trial results in a formal network meta-analysis, differences in control trial samples meant that these comparisons were unsound and these results are not reported. Informal indirect comparisons are discussed.

Heterogeneity between studies was represented by the I^2^ statistic and the χ^2^ test for heterogeneity \[[@R23]\]. In order to investigate the sources of heterogeneity the combined treatment effects for AHI and ESS were re-estimated in each of the following subgroups.

1.  Mean baseline AHI events/hour: mild (AHI 5--14), moderate (AHI 15--30) and severe (AHI \> 30). If only mean DI, rather than mean AHI was available, severity was classified as: mild (DI 5--9), moderate (DI 10--30) and severe (DI \> 30).

2.  Mean baseline ESS score: normal/mild (0--9), moderate (10--15) and severe (16--24)

3.  Study design: parallel and crossover

4.  Treatment duration for studies involving MAD: short (2--12 wk) and long (\>12 wk), and for studies of CPAP against CM: short (2--4 wk) medium (5--12 wk) and long (\>12 wk)

Results {#S14}
=======

Quantity and quality of studies {#S15}
-------------------------------

Results of the literature search are summarised in [Fig. 1](#F1){ref-type="fig"}. After combining studies identified in previous reviews which had not been superceded by subsequent reports (44 studies) with those identified in the current review (27 studies) 71 trials were included. Three studies compared MAD, CPAP and CM and so each contribute to three separate comparisons, giving a total of 77 separate comparisons \[[@R24]--[@R26]\]. Most studies focussed on the effectiveness of CPAP.

Summary of included studies {#S16}
---------------------------

Summaries of the baseline characteristics for the included studies are shown in [Table 1](#T1){ref-type="table"}. Twelve studies (629 patients) compared MAD against CM, 13 studies (746 patients) compared MAD against CPAP and 52 studies (5400 patients) compared CPAP with CM.

Patient characteristics {#S17}
-----------------------

As expected the study samples included a large proportion of men, ranging from 65% to 100%, median 81%. The reported mean ages ranged from 44.0 to 59.2 y. Most trial samples were over-weight or obese on average, with mean body mass index ranging from 28.3 kg/m^2^ to 35.1 kg/m^2^.

In general CPAP trials were conducted in patient samples with more severe AHI/ESS at baseline than were MAD trials. Of 51 CPAP-CM comparisons that recorded average baseline AHI, 35 (69%) were in patients with an average AHI greater than 30 events/hour (severe OSAH) compared with three of 12 (25%) MAD-CM trials. Only five CPAP-CM trials were in patients with mild AHI at baseline. Most MAD-CM trials (seven of 12, 58%) were in patients with moderate AHI at baseline. In trials directly comparing MAD with CPAP, one did not record baseline AHI, eight of the remaining 12 (67%) reported moderate and four (33%) reported severe average baseline AHI.

Average baseline ESS was available for 60 comparisons. Of these, all nine MAD-CPAP trials and seven of the eight (88%) MAD-CM trials reported moderate mean baseline ESS. Of the 43 CPAP-CM comparisons, six (14%) had normal/mild, 32 (74%) had moderate and five (12%) had severe mean baseline daytime sleepiness according to ESS.

Intervention and comparators {#S18}
----------------------------

Thirteen (53%) of 25 trials involving MAD used adjustable devices, 10 (40%) used fixed devices and two (8%) did not report the type. In 13 trials (52%) the MAD was compared directly with CPAP, nine (36%) used a sham MAD, one compared MAD with a placebo tablet, one with conservative treatment and one with no treatment.

Of 65 trials involving CPAP 54 (83%) used fixed CPAP, six (9%) autotitrating machines and five (8%) did not report this information. Excluding the 13 trials comparing CPAP with MAD, 29 of 52 (56%) compared CPAP with a sham version, seven (13%) with placebo tablet and nine (13%) with conservative management or no treatment.

Study design {#S19}
------------

Trials were almost invariably small (see [Table 1](#T1){ref-type="table"}). The median number of patients randomised in MAD-CM trials was 48 (range 21--91), in MAD-CPAP trials 51 (range 20--122) and in CPAP-CM 52 (range 10 to 1105). Duration of treatment was generally short, with 60 of 76 (79%) trials that reported duration having a treatment period of 12 wk or less. Nine of 13 (69%) MAD-CPAP trials had a crossover design, compared with six of 12 (50%) MAD-CM trials and 16 of 52 (31%) CPAP-CM trials.

Study quality {#S20}
-------------

The Jadad score was available for 69 of the 71 trials, with average score close to three for comparisons against CM. The mean Jadad score was 2.9 in MAD-CM trials, 2.3 in MAD-CPAP comparisons and 3.1 in CPAP-CM trials, with the lower mean scores in MAD-CPAP comparisons mainly attributable to the difficulty in blinding the two active treatments.

Apnoea-hypopnoea index {#S21}
----------------------

### MAD compared with CM {#S22}

Twelve studies (629 patients) provided an estimate of the effect on AHI, but one of these \[[@R27]\] only provided a point estimate and could not be included in the meta-analysis (see [Fig. 2](#F2){ref-type="fig"}). The mean difference (reduction) in AHI for MAD compared with CM was −9.29 events/hour, (95%CI −12.28, −6.30), p \< 0.001. There was significant heterogeneity between studies (I^2^ = 60%, p = 0.005), partly arising from differences in baseline severity of AHI. Only two studies were in patients with mild OSAH and the treatment effect for these studies differed by more than nine events per hour. Six of the 11 studies had a crossover design and these studies had more heterogeneous results than parallel group trials (see [Table 2](#T2){ref-type="table"}). Treatment effects were greater in crossover trials than in parallel group designs, although the difference between designs was not large. In addition, treatment effects in trials of short duration were larger than in longer-term studies.

### MAD compared with CPAP {#S23}

From 13 trials (746 patients) the estimated overall difference in AHI was 7.03 events/hour (95%CI 5.41, 8.66), p \< 0.001, with CPAP having lower post-treatment AHI than MAD (see [Fig. 3](#F3){ref-type="fig"}). Again there was important heterogeneity between study results, with smaller studies \[[@R28]--[@R31]\] and shorter studies \[[@R28],[@R29],[@R31]\], estimating greater effects than larger and longer studies. No MAD-CPAP head-to-head comparisons were reported in patients with mild baseline AHI (see [Table 3](#T3){ref-type="table"}) and all nine trials reported moderate average ESS at baseline. Estimates of the difference in post-treatment AHI were consistent and were not related to baseline AHI (moderate compared with severe), trial design or duration of treatment, with all significantly lower, by approximately seven events per hour, after CPAP (see [Table 3](#T3){ref-type="table"}).

### CPAP compared with CM {#S24}

Of 52 CPAP-CM trials, 25 (1596 patients) reported post-treatment AHI, with combined effect of −25.37 events/hour (95% CI −30.67, −20.07), p \< 0.001 (see [Fig. 4](#F4){ref-type="fig"}). There was a significant amount of heterogeneity between study results, both overall and within strata. Some heterogeneity could be explained by baseline AHI severity and the potential for treatment effect is naturally governed by the extent of disease in the sample. Only one of these studies was in patients with mild baseline AHI \[[@R32]\] and the estimated mean effect in this trial was small at −2.40 events/hour (95% CI −3.67, −1.13). The mean difference in AHI between CPAP and CM patients increased with baseline severity, from −13.67 events/hour (95%CI −16.13, −11.20) for moderate AHI at baseline to −33.04 events/hour (95%CI −39.75, −26.34) for severe (see [Table 4](#T4){ref-type="table"}). One trial reported normal/mild ESS at baseline but, despite this, baseline AHI was severe and the treatment effect was large. With the exception of this study the effect of CPAP on AHI was related to baseline ESS severity. There was some evidence that the treatment was less effective in crossover trials compared with parallel group trials. In common with MAD-CM comparisons, trials with longer treatment duration had lower treatment effects than shorter trials (see [Table 4](#T4){ref-type="table"}).

Epworth sleepiness scale {#S25}
------------------------

### MAD compared with CM {#S26}

Ten studies reported a point estimate for ESS but only nine reported the standard error of the treatment effect and so could be included in the meta-analysis. For these nine studies (485 patients) the combined treatment effect on ESS was −1.64 (−2.46, −0.82) (see [Fig. 5](#F5){ref-type="fig"} and [Table 5](#T5){ref-type="table"}). There was significant heterogeneity, with small studies \[[@R33],[@R34]\] more likely to report large treatment differences (see [Fig. 5](#F5){ref-type="fig"}). One study was conducted in patients with mild AHI at baseline and the effect on ESS in this study was between, and of a similar order to, estimates from trials in patient populations with moderate and severe baseline AHI \[[@R35]\]. Due to the small number of trials and the large influence of the Blanco et al. \[[@R34]\] study it was not possible to reliably assess reasons for heterogeneity.

### MAD compared with CPAP {#S27}

Of the 12 studies directly comparing MAD and CPAP 10 trials (675 patients) recorded ESS with a combined effect of 0.67 (95%CI −0.11, 1.44), p = 0.093 (see [Fig. 6](#F6){ref-type="fig"}). The positive estimate indicates that the post-treatment ESS was lower (better) in the CPAP group. There was less between-study heterogeneity in this analysis and results of stratified analysis show that any treatment effect was small, with clinically significant differences only likely for those with severe baseline AHI (see [Table 6](#T6){ref-type="table"}). However the number and size of trials made reliable conclusions impossible, particularly regarding mild OSAH.

### CPAP compared with CM {#S28}

Thirty-eight of the 52 CPAP-CM trials (4894 patients) reported the estimated post-treatment effect on ESS. These trials were plotted in [Fig. 7](#F7){ref-type="fig"} with combined treatment effect of −2.23 (95% CI −2.76, −1.71), p \< 0.001. Again there was significant heterogeneity, and some stratified analyses were reported in [Table 7](#T7){ref-type="table"}. In common with AHI the effect of CPAP on ESS increased with baseline AHI severity, from −1.23 (95%CI −2.19, −0.27) for the mild group to −2.64 (95%CI −3.44, −1.84) for the severe group. One study did not report baseline AHI. Trial design had less impact on outcomes but longer duration of treatment was associated with decreasing treatment effect, which again mirrors the analysis of AHI.

Discussion {#S29}
==========

Our study was based on a systematic review of the available literature and robust, prospective design. The updated meta-analyses offer stronger insights into the relative effectiveness of MAD and CPAP in patients with mild-moderate OSAH. In addition the effects of baseline severity have been highlighted and used to explain some of the differences in effects between MAD and CPAP.

The three pairwise meta-analyses have shown that MAD results in a significant improvement in post-treatment AHI, and that the estimate of effect was similar irrespective of baseline AHI. CPAP produces an improvement of approximately three times that of the combined estimate for MAD. However, the majority of trials involving CPAP focus on patients with severe baseline AHI and there was strong evidence that the treatment effect, compared with CM, was related to baseline AHI severity, which is natural since a higher baseline allows greater scope for an absolute decrease. In trials directly comparing MAD with CPAP the combined estimates favour CPAP but the absolute difference between them was of the order of seven events per hour, much less than suggested by indirectly comparing MAD-CM and CPAP-CM trials. In the few trials of patients with mild baseline AHI, compared with CM the estimated reduction in AHI due to CPAP was −2.4 events/hour (95%CI −1.13, −3.67) and due to MAD was −7.79 events/hour (95%CI −16.38, 0.79). Moreover, there were no MAD-CPAP trials conducted in patients with mild average baseline AHI. This evidence suggests that CPAP results in greater overall effect on post-treatment AHI but the improvement over MAD will be lower in mild disease.

The effect of MAD on subjective daytime sleepiness measured using the ESS followed a similar pattern but this instrument was less sensitive to differences than AHI, so that differences in treatment effects between MAD and CPAP were smaller and not significant in direct comparisons. From trials of CPAP against CM the estimated effects were related to baseline EDS severity with treatment effects (95%CI) on ESS of −0.83 (−1.16, −0.51) for normal/mild, −2.19 (−2.84, 1.53) for moderate and −4.99 (−6.51, −3.47) for severe baseline ESS. This relationship between baseline severity and effect on ESS was also observed when severity was classified by average baseline AHI. When trials of similar baseline characteristics were compared there was little difference between the effects of MAD and CPAP on post-treatment ESS when assessed against CM, and this was reinforced by the results from head-to-head trials. In the few trials conducted in patients with mild baseline AHI, compared with CM the estimated reduction in ESS due to CPAP was −1.23 (95%CI −2.19, −0.27) and due to MAD was −2.01 (95% CI −2.70, −1.32).

There was some evidence that treatment effects were stronger in trials of short duration of treatment, which may have a number of causes. CPAP is intrusive, requiring patients to wear a face mask during sleep, and there is evidence for a tailing-off of compliance over time \[[@R17]\]. Although there is some evidence that MAD may be better tolerated than CPAP in the short term \[[@R36]--[@R38]\], the limited longer-term data available suggest that compliance with this less intrusive intervention also diminishes with time \[[@R39],[@R40]\]. For both active treatments progression of the underlying OSAH may mean that treatment effects decreased over time. Possible candidate mechanisms would be ageing and weight gain. Age effects would not be expected to manifest over the relatively short periods that trials run \[[@R41],[@R42]\]. The evidence for CPAP use being associated with weight gain remains unclear but even when demonstrated the degree of increase seems too small to impact significantly on treated OSAH \[[@R43]\]. In any case, the range of trial durations in this meta-analysis was narrow, and there were too few trials (and patients) to examine this observation in detail. Further trials and, more importantly, availability of individual patient data from all trials, would allow indepth examination of the characteristics of patients that determine outcomes.

In almost all comparisons there was significant heterogeneity between trials. Although some of this could be explained by disease severity, design and treatment duration, unexplained heterogeneity remains. Although we used random-effects meta-analysis to provide unbiased point estimates and robust estimates of precision, further elucidation of the sources of heterogeneity would be useful. Routine release of anonymised, individual patient data after trials have been reported would allow greater exploration of the variation in treatment outcomes. We strongly support initiatives such as the Farr Institute in making such data freely available.

Limitations {#S30}
-----------

In the meta-analysis we considered all MAD as a single treatment modality. There were too few studies to allow robust subgroup analyses and so we were unable to identify the more modest differences in effects between different MAD. It has been suggested that future meta-analyses distinguish between trials of non-adjustable MAD and those using adjustable MAD (aMAD) \[[@R44]\]. From the 2006 Cochrane analysis that included only trials comparing CPAP with aMAD, the ESS effect size was in favour of MAD, but not significantly \[[@R15]\]. We considered performing a similar subgroup analysis when updating the meta-analysis. However, device adjustability could not always be determined \[[@R31],[@R45]\]. In any case, to subdivide along these lines may be too simplistic. For example, one trial with relatively weak treatment effects has previously been excluded from aMAD reviews, as they used two non-adjustable MAD \[[@R46]\]. However they performed 'pseudotitration' by adapting devices to optimise comfort and benefits, and reported near maximal (80%) jaw protrusion. Meanwhile the potential advantage of titratable aMAD has sometimes been negated by the use of uniform protrusion for all patients \[[@R30]\].

Three separate meta-analyses were conducted comparing MAD against CM, MAD against CPAP and CPAP against CM. A more sophisticated analysis would combine the studies into a formal network meta-analysis, thereby adding strength to all comparisons and better aligning the studies. Whilst this method was investigated, such analyses rely on the assumption of common control populations (the associative law), which was unlikely to be true in this case, given the greater severity of OSAH in samples undergoing trials of CPAP. Furthermore the heterogeneity observed between studies suggested that combining results within and across different treatments may not be sensible. The likely implication of doing separate meta-analyses would be a loss of precision.

CM encompassed a wide range of control treatments so that their influence on the trial-based treatment effects was difficult to estimate with any precision.

In our systematic review we used the Jadad score as a measure of study quality which is rather an insensitive tool. It did, however, provide a broad structure for summarising design features reported in existing clinical trials.

We restricted this analysis to the two most frequently used outcome measures in RCTs of OSA treatment and in clinical practice. Other important clinical outcomes, such as hypertension, were not always available in published studies, and when they were the specific measurement reported was not consistent. In addition, a wide range of quality of life instruments have been used and robust meta-analysis of these outcomes has not been possible.

Where there was uncertainty regarding published evidence we were able to contact authors of trials of MAD but, due to the much larger number of studies, this was not possible for CPAP trials. However this mainly applied to trials that were only published in abstract form and is not likely to have introduced important bias.

Conclusions {#S31}
===========

For patients with moderate to severe OSAH treatment with CPAP was the most clinically-effective approach to reduction in the AHI. For individual patients who are intolerant of CPAP, treatment with a MAD may also be effective in reducing the AHI compared with no treatment. Both treatments were effective in reducing ESS, with CPAP having only a small, additional effect over MADs. In the few trials of patients with mild OSAH, CPAP and MAD were similarly effective treatment options and there was little to choose between them in terms of clinical-effectiveness. There was significant heterogeneity between patients in response to treatment, some of which could be explained by severity of OSAH at baseline (differences in the effect sizes for CPAP and MAD increased with baseline severity) and duration of treatment. Furthermore, there is unavoidable overlap between the arbitrarily defined severity groups, which introduces ambiguity. However, reliable stratification of patients for management will only be possible if anonymised individual patient data from these studies can be made available.
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AASM

:   American Academy of Sleep Medicine

AHI

:   apnoea--hypopnoea index

aMAD

:   adjustable mandibular advancement device

CI

:   confidence interval

CM

:   conservative management

CPAP

:   continuous positive airway pressure

CVD

:   cardiovascular disease

DI

:   desaturation index

EDS

:   excessive daytime sleepiness
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:   effect size

ESS

:   Epworth sleepiness scale

HRQoL

:   health-related quality of life

ID

:   identification

MAD

:   mandibular advancement device

OSAH

:   obstructive sleep apnoea--hypopnoea

RCT

:   randomised controlled trial

RTA

:   road traffic accident

Practice points {#S33}
===============

This meta-analysis shows that: CPAP is the most clinically effective treatment at reducing AHI in moderate to severe OSAH.Both CPAP and MAD reduce subjective sleepiness to a similar extent in OSAHS.MAD are better than no treatment for CPAP-intolerant patients and, based on indirect comparisons, may be as effective as CPAP in mild disease.

Research agenda {#S34}
===============

Future research needs to address: whether adjustable MAD offer additional benefits in terms of treatment outcomes over non-titratable devices, using prospective head-to-head trials.using evidence obtained from (1) the comparative effectiveness of optimal MAD therapy and CPAP in mild OSAHS.the need for reliable stratification of patients for management using data from existing studies.the need to continue to explore the effectiveness and costs of clinical strategies to predict individual patients\' responses to MAD, to refine treatment choice and effectiveness in OSAHS.

![Results of the literature search. Abbreviations: CPAP: continuous positive airway pressure; MAD: mandibular advancement device; TOMADO: trial of oral mandibular advanacement devices for obstructive sleep apnoea.](emss-71929-f001){#F1}

![Meta-analysis of AHI results from trials of MAD compared with conservative management, stratified by baseline AHI. Mean baseline AHI/DI (events/hour); mild (AHI 5--14, DI 5--9) moderate (AHI 15--30 DI 10--30) severe (AHI \> 30 DI \> 30). Abbreviations: AHI: apnoea-hypopnoea index; CI: confidence interval; continuous positive airway pressure (CPAP); DI: desaturation index; ES: effect size; ID: identification; MAD: mandibular advancement device.](emss-71929-f002){#F2}

![Meta-analysis of AHI results from trials of MAD compared with CPAP. Mean baseline AHI/DI (events/hour): mild (AHI 5--14, DI 5--9), moderate (AHI 15--30 DI 10--30) and severe (AHI \> 30 DI \> 30). Abbreviations: AHI: apnoea-hypopnoea index; CI: confidence interval; CPAP: continuous positive airway pressure; DI: desaturation index; ES: effect size; ID: Identification; MAD: mandibular advancement device; NR: baseline AHI not recorded.](emss-71929-f003){#F3}

![Meta-analysis of AHI results from trials of CPAP compared with conservative management, stratified by baseline AHI. Mean baseline AHI/DI (events/hour): mild (AHI 5--14, DI 5--9), moderate (AHI 15--30 DI 10--30) and severe (AHI \> 30 DI \> 30). Abbreviations: AHI: apnoea-hypopnoea index; CI: confidence interval; CPAP: continuous positive airway pressure; DI: desaturation index; ES: effect size; ID: identification.](emss-71929-f004){#F4}

![Meta-analysis of ESS results from trials of MAD compared with conservative management, stratified by baseline AHI. Mean baseline Apnoea-Hypopnoea Index/Desaturation Index (AHI/DI) events/hour: mild (AHI 5--14, DI 5--9) moderate (AHI 15--30 DI 10--30) severe (AHI \> 30 DI \> 30). Abbreviations: AHI: apnoea-hypopnoea index; CI: confidence interval; DI: desaturation index; ES: effect size; ESS: Epworth Sleepiness Scale; ID: identification; MAD: mandibular advancement device.](emss-71929-f005){#F5}

![Meta-analysis of ESS results from trials of MAD compared with CPAP, stratified by baseline AHI. Mean baseline AHI/DI (events/hour): mild (AHI 5--14, DI 5--9), moderate (AHI 15--30 DI 10--30) and severe (AHI \> 30 DI \> 30). Abbreviations: AHI: apnoea-hypopnoea index; CI: confidence interval; CPAP: continuous positive airway pressure; DI: desaturation index; ES: effect size; ESS: Epworth Sleepiness Scale; ID: identification; MAD: mandibular advancement device.](emss-71929-f006){#F6}

![Meta-analysis of ESS results from trials of CPAP compared with conservative management. Mean baseline AHI/DI (events/hour): mild (AHI 5--14, DI 5--9), moderate (AHI 15--30 DI 10--30) and severe (AHI \> 30 DI \> 30). Abbreviations: apnoea-hypopnoea index (AHI); confidence interval (CI); continuous positive airway pressure (CPAP); desaturation index (DI); effect size (ES); Epworth sleepiness scale (ESS); identification (ID); baseline AHI not recorded (NR).](emss-71929-f007){#F7}

###### 

Baseline characteristics of patients and study designs for randomised controlled trials.

  Study                                     Design   Number randomised (analysed)   Baseline severity (AHI or DI)   Baseline symptom severity (ESS)   Duration of each treatment (weeks)
  ----------------------------------------- -------- ------------------------------ ------------------------------- --------------------------------- ------------------------------------
  **MAD compared with CM**                                                                                                                            
  Aarab et al. 2011 \[[@R26]\]              P        42                             Moderate                        Moderate                          26
  Andren et al. 2013 \[[@R27]\]             P        72                             Moderate                        Moderate                          13
  Barnes et al. 2004 \[[@R24]\]             C        80                             Moderate                        Moderate                          12
  Blanco et al. 2005 \[[@R34]\]             P        24 (15)                        Severe                          Severe                            13
  Duran et al. 2002 \[[@R47]\]              C        44 (38)                        Mild                            NR                                NR
  Gotsopoulos et al. 2002 \[[@R48]\]        C        85 (73)                        Moderate                        NR                                4
  Hans et al. 1997 \[[@R33]\]               P        24                             Moderate                        NR                                NR
  Johnston et al. 2002 \[[@R49]\]           C        21 (18)                        Severe                          Moderate                          4--6
  Lam et al. 2007 \[[@R25]\]                P        67                             Moderate                        Moderate                          10
  Mehta et al. 2001 \[[@R50]\]              C        28                             Moderate                        NR                                3
  Petri et al. 2008 \[[@R51]\]              P        52                             Severe                          Moderate                          4
  Quinnell et al. 2014 \[[@R35]\]           P        90                             Mild                            Moderate                          4
  **MAD compared with CPAP**                                                                                                                          
  Aarab et al. 2011 \[[@R26]\]              P        43                             Moderate                        Moderate                          26
  Barnes et al. 2004 \[[@R24]\]             C        80                             Moderate                        Moderate                          12
  Engelman et al. 2002 \[[@R46]\]           C        51 (48)                        Severe                          Moderate                          8
  Ferguson et al. 1996 \[[@R29]\]           C        27                             Moderate                        NR                                17
  Ferguson et al. 1997 \[[@R28]\]           C        24 (19)                        Moderate                        NR                                17
  Fleetham et al. 1998 \[[@R31]\]           P        101                            Severe                          Moderate                          12
  Hoekema et al. 2008 \[[@R52]\]            P        103                            Severe                          Moderate                          8
  Gagnadoux et al. 2009 \[[@R53]\]          C        59                             Severe                          Moderate                          8
  Lam et al. 2007 \[[@R25]\]                P        68                             Moderate                        Moderate                          10
  Olson et al. 2002 \[[@R45]\]              C        24                             NR                              NR                                14
  Phillips et al. 2013 \[[@R36]\]           C        122                            Moderate                        Moderate                          4
  Randerath et al. 2002 \[[@R30]\]          C        20                             Moderate                        NR                                6
  Tan et al. 2002 \[[@R54]\]                C        24 (21)                        Moderate                        Moderate                          8
  **CPAP compared with CM**                                                                                                                           
  Aarab et al. 2011 \[[@R26]\]              P        43                             Moderate                        Moderate                          26
  Arias et al. 2005 \[[@R55]\]              C        27                             Severe                          NR                                12
  Arias et al. 2006 \[[@R56]\]              P        23                             Severe                          NR                                12
  Ballester et al. 1999 \[[@R57]\]          P        105                            Severe                          Moderate                          12
  Barbe et al. 2001 \[[@R58]\]              P        55                             Severe                          Normal/Mild                       6
  Barbe et al. 2012 \[[@R59]\]              P        725                            Severe                          Normal/Mild                       156
  Barnes et al. 2002 \[[@R60]\]             C        42                             Mild                            Moderate                          8
  Barnes et al. 2004 \[[@R24]\]             C        80                             Moderate                        Moderate                          12
  Becker et al. 2003 \[[@R61]\]             P        60                             Severe                          Moderate                          9
  Campos-Rodriguez et al. 2006 \[[@R62]\]   P        72                             Severe                          Moderate                          4
  Chakravorty et al. 2002 \[[@R63]\]        P        71                             Severe                          Severe                            12
  Coughlin et al. 2007 \[[@R64]\]           C        35                             Severe                          Moderate                          6
  Craig et al. 2012 \[[@R65]\]              P        391                            Mild                            Normal/Mild                       26
  Diafera et al. 2013 \[[@R66]\]            P        100                            Severe                          Moderate                          13
  Drager et al. 2006 \[[@R67]\]             P        16                             Severe                          NR                                12
  Drager et al. 2007 \[[@R68]\]             P        24                             Severe                          Moderate                          17
  Duran-Cantolla et al. 2010 \[[@R69]\]     P        340                            Severe                          Moderate                          12
  Engleman et al. 1996 \[[@R70]\]           C        16                             Severe                          NR                                3
  Engleman et al. 1997 \[[@R71]\]           C        18                             Mild                            Moderate                          4
  Engleman et al. 1998 \[[@R72]\]           C        23                             Severe                          Moderate                          4
  Engleman et al. 1999 \[[@R73]\]           C        37                             Mild                            Moderate                          4
  Faccenda et al. 2001 \[[@R74]\]           C        71                             Severe                          Moderate                          4
  Haensel et al. 2007 \[[@R75]\]            P        50                             Severe                          NR                                2
  Henke et al. 2001 \[[@R76]\]              P        45                             Severe                          Severe                            2
  Hoyos et al. 2012 \[[@R77]\]              P        65                             Severe                          Moderate                          12
  Hui et al. 2006 \[[@R78]\]                P        56                             Severe                          Moderate                          12
  Jenkinson et al. 1999 \[[@R79]\]          P        107                            Moderate                        Severe                            4
  Kaneko et al. 2003 \[[@R80]\]             P        21                             Severe                          Normal/Mild                       4
  Kushida et al. 2012 \[[@R81]\]            P        1105                           Severe                          Moderate                          26
  Lam et al. 2007 \[[@R25]\]                P        67                             Moderate                        Moderate                          10
  Lee et al. 2012 \[[@R82]\]                P        71                             Severe                          Moderate                          3
  Lozano et al. 2010 \[[@R83]\]             P        75                             Severe                          Normal/Mild                       13
  Mansfield et al. 2004 \[[@R84]\]          P        55                             Moderate                        Moderate                          12
  Marshall et al. 2005 \[[@R85]\]           C        31                             Moderate                        Moderate                          3
  Monasterio et al. 2001 \[[@R86]\]         P        142                            Moderate                        Moderate                          24
  Montserrat et al. 2001 \[[@R87]\]         P        46                             Severe                          Severe                            6
  Norman et al. 2006 \[[@R88]\]             P        33                             Severe                          Moderate                          2
  Pepperell et al. 2002 \[[@R16]\]          P        118                            Severe                          Severe                            4
  Phillips et al. 2011 \[[@R89]\]           C        20                             Severe                          Moderate                          8
  Redline et al. 1998 \[[@R90]\]            P        111                            Moderate                        Moderate                          8
  Robinson et al. 2006 \[[@R91]\]           C        35                             Moderate                        Normal/Mild                       4
  Sharma et al. 2011 \[[@R92]\]             C        90                             Severe                          Moderate                          13
  Siccoli et al. 2008 \[[@R14]\]            P        102                            Severe                          Moderate                          4
  Simpson et al. 2012 \[[@R93]\]            P        36                             Severe                          NR                                12
  Skinner et al. 2004 \[[@R94]\]            C        10                             Moderate                        Moderate                          4
  Skinner et al. 2008 \[[@R95]\]            C        20                             Moderate                        Moderate                          4
  Spicuzza et al. 2006 \[[@R96]\]           P        25                             Severe                          NR                                4
  Tomfohr et al. 2011 \[[@R97]\]            P        71                             Severe                          Moderate                          3
  Von Kanel et al. 2006 \[[@R98]\]          P        28                             Severe                          NR                                2
  Weaver et al. 2012 \[[@R32]\]             P        281                            Mild                            Moderate                          8
  Weinstock et al. 2012 \[[@R99]\]          C        50                             Severe                          NR                                8
  West et al. 2007 \[[@R100]\]              P        42                             NR                              Moderate                          12

Mean baseline AHI (or DI if AHI not reported) events/hour: mild (AHI 5--14, DI 5--9), moderate (AHI 15--30, DI 10--30) and severe (AHI \> 30, DI \> 30).

Mean baseline ESS 0--9 (normal/mild) 10--15 (moderate) 16--24 (severe).

Abbreviations: apnoea-hypopnoea index (AHI); CPAP: continuous positive airway pressure; C: Crossover; DI: desaturation index; ESS: Epworth Sleepiness Score; MAD: mandibular advancement device; NR: not recorded or unclear; P: parallel.

###### 

Subgroup analysis of AHI results (events per hour) for comparisons of MAD against conservative management (negative estimates favour MAD).

  Subgroup                                                  Number of studies   Difference in AHI: MAD-control (95%CI)   P value for effect   I^2^   Heterogeneity P value
  --------------------------------------------------------- ------------------- ---------------------------------------- -------------------- ------ -----------------------
  **Baseline AHI**                                                                                                                                   
  Mild \[[@R35],[@R47]\]                                    2                   −7.79 (−16.38, 0.79)                     0.075                65%    0.091
  Moderate \[[@R24]--[@R26],[@R33],[@R48],[@R50]\]          6                   −10.72 (−14.59, −6.85)                   \<0.001              52%    0.064
  Severe \[[@R24],[@R49],[@R51]\]                           3                   −7.95 (−15.94, 0.05)                     0.051                32%    0.232
  **Baseline ESS**                                                                                                                                   
  Moderate \[[@R24]--[@R26],[@R35],[@R49],[@R51]\]          6                   −6.69 (−8.98, −4.41)                     \<0.001              35%    0.177
  Severe \[[@R34]\]                                         1                   −2.10 (−12.33, 8.13)                     0.687                −      −
  **Trial design**                                                                                                                                   
  Crossover \[[@R24],[@R35],[@R47]--[@R50]\]                6                   −10.17 (−14.27, −6.07)                   \<0.001              76%    0.001
  Parallel \[[@R25],[@R26],[@R33],[@R34],[@R51]\]           5                   −8.57 (−12.39, −4.75)                    \<0.001              0%     0.533
  **Duration of treatment**                                                                                                                          
  2--12 wk \[[@R24],[@R25],[@R33],[@R35],[@R48]--[@R51]\]   8                   −9.69 (−13.27, −6.12)                    \<0.001              68%    0.003
  \>12 wk \[[@R26],[@R34]\]                                 2                   −6.78 (−13.24, −0.33)                    0.039                23%    0.56
  **Overall MAD compared with control**                                                                                                              
  Overall                                                   11                  −9.29 (−12.28, −6.30)                    \<0.001              60%    0.005

Mean baseline AHI (or DI if AHI not reported) events/hour: mild (AHI 5--14, DI 5--9), moderate (AHI 15--30, DI 10--30) and severe (AHI \> 30, DI \> 30).

Mean baseline ESS score: normal/mild (0--9), moderate (10--15) and severe (16--24).

Abbreviations: AHI: apnoea-hypopnoea index; CI: confidence interval; DI: desaturation index; I^2^: proportion of total variability explained by heterogeneity; MAD: mandibular advancement device.

###### 

Subgroup analysis of AHI results (events per hour) for comparison of MAD against CPAP (positive estimates favour CPAP).

  Subgroup                                                                 Number of studies   Difference in AHI: MAD-CPAP (95%CI)   P value for effect   I^2^   Heterogeneity P value
  ------------------------------------------------------------------------ ------------------- ------------------------------------- -------------------- ------ -----------------------
  **Baseline AHI** (1 study did not record baseline AHI)                                                                                                         
  Moderate \[[@R24]--[@R26],[@R28]--[@R30],[@R36],[@R54]\]                 8                   7.48 (5.77, 9.19)                     \<0.001              28%    0.203
  Severe \[[@R31],[@R46],[@R52],[@R53]\]                                   4                   7.22 (3.20, 11.25)                    \<0.001              74%    0.010
  **Baseline ESS**                                                                                                                                               
  Moderate \[[@R24]--[@R26],[@R31],[@R36],[@R46],[@R52]--[@R54]\]          9                   6.70 (4.86, 8.54)                     \<0.001              57%    0.098
  **Trial design**                                                                                                                                               
  Crossover \[[@R24],[@R28]--[@R30],[@R36],[@R45],[@R46],[@R53],[@R54]\]   9                   6.91 (5.11, 8.71)                     \<0.001              48%    0.054
  Parallel \[[@R25],[@R26],[@R31],[@R52]\]                                 4                   7.72 (3.58, 11.87)                    \<0.001              69%    0.022
  **Duration of treatment**                                                                                                                                      
  2--12 wk \[[@R24],[@R25],[@R30],[@R31],[@R36],[@R46],[@R52]--[@R54]\]    9                   7.19 (5.25, 9.12)                     \<0.001              59%    0.013
  \>12 wk \[[@R26],[@R28],[@R29],[@R45]\]                                  4                   6.78 (3.25, 10.31)                    \<0.001              42%    0.157
  **Overall MAD compared with CPAP**                                                                                                                             
  Overall                                                                  13                  7.03 (5.41, 8.66)                     \<0.001              52%    0.015

Mean baseline AHI (or DI if AHI not reported) events/hour: mild (AHI 5--14, DI 5--9), moderate (AHI 15--30, DI 10--30) and severe (AHI \> 30, DI \> 30).

Mean baseline ESS score: normal/mild (0--9), moderate (10--15) and severe (16--24).

Abbreviations: AHI: apnoea-hypopnoea index; CI: confidence interval; CPAP: continuous positive airway pressure; DI: desaturation index; I^2^: proportion of total variability explained by heterogeneity; MAD: mandibular advancement device.

###### 

Subgroup analysis of AHI results (events/hour) for comparison of CPAP against conservative management (negative estimates favour CPAP).

  Subgroup                                                                                                                                       Number of studies   Difference in AHI: CPAP-control (95%CI)   P value for effect   I^2^   Heterogeneity P value
  ---------------------------------------------------------------------------------------------------------------------------------------------- ------------------- ----------------------------------------- -------------------- ------ -----------------------
  **Baseline AHI**                                                                                                                                                                                                                         
  Mild \[[@R32]\]                                                                                                                                1                   −2.40 (−3.67, −1.13)                      \<0.001              --     --
  Moderate \[[@R24]--[@R26],[@R84],[@R86],[@R94],[@R95]\]                                                                                        7                   −13.67 (−16.13, −11.20)                   \<0.001              47%    0.081
  Severe \[[@R16],[@R61],[@R63],[@R66],[@R67],[@R75]--[@R77],[@R80],[@R82],[@R88],[@R89],[@R93],[@R96]--[@R99]\]                                 17                  −33.04 (−39.75, −26.34)                   \<0.001              90%    \<0.001
  **Baseline ESS**                                                                                                                                                                                                                         
  Normal/Mild \[[@R80]\]                                                                                                                         1                   −32.50 (−43.55, −21.45)                   \<0.001              --     --
  Moderate \[[@R24]--[@R26],[@R32],[@R61],[@R66],[@R77],[@R82],[@R84],[@R86],[@R88],[@R89],[@R94],[@R95],[@R97]\]                                15                  −17.54 (−22.51, −12.56)                   \<0.001              95%    \<0.001
  Severe \[[@R16],[@R63],[@R76]\]                                                                                                                3                   −34.73 (−58.90, −10.57)                   0.005                95%    \<0.001
  **Trial design**                                                                                                                                                                                                                         
  Crossover \[[@R24],[@R89],[@R94],[@R95],[@R99]\]                                                                                               5                   −19.71 (−27.95, −11.48)                   \<0.001              87%    \<0.001
  Parallel \[[@R16],[@R25],[@R26],[@R32],[@R61],[@R63],[@R66],[@R67],[@R75]--[@R77],[@R80],[@R82],[@R84],[@R86],[@R88],[@R93],[@R96]--[@R98]\]   20                  −27.08 (−33.68, −20.48)                   \<0.001              97%    \<0.001
  **Duration of treatment**                                                                                                                                                                                                                
  2--4 wk \[[@R16],[@R75],[@R76],[@R80],[@R82],[@R88],[@R94]--[@R98]\]                                                                           11                  −32.90 (−43.78, −22.02)                   \<0.001              93%    \<0.001
  5--12 wk \[[@R24],[@R25],[@R32],[@R61],[@R63],[@R67],[@R77],[@R84],[@R89],[@R93],[@R99]\]                                                      11                  −22.34 (−29.84, −14.85)                   \<0.001              96%    \<0.001
  \>12 wk \[[@R26],[@R66],[@R86]\]                                                                                                               3                   −14.25 (−19.03, −9.46)                    \<0.001              82%    0.004
  **Overall CPAP compared with controls**                                                                                                                                                                                                  
  Overall                                                                                                                                        25                  −25.37 (−30.67, −20.07)                   \<0.001              96%    \<0.001

Mean baseline AHI (or DI if AHI not reported) events/hour: mild (AHI 5--14, DI 5--9), moderate (AHI 15--30, DI 10--30) and severe (AHI \> 30, DI \> 30).

Mean baseline ESS score: normal/mild (0--9), moderate (10--15) and severe (16--24).

Abbreviations: AHI: apnoea-hypopnoea index; CI: confidence interval; CPAP: continuous positive airway pressure; DI: desaturation index; I^2^ proportion of total variability explained by heterogeneity.

###### 

Subgroup analysis of ESS results for comparison of MAD against conservative management (negative estimates favour MAD).

  Subgroup                                                        Number of studies   Difference in ESS: MAD-controls (95%CI)   P value for effect   I^2^   Heterogeneity P value
  --------------------------------------------------------------- ------------------- ----------------------------------------- -------------------- ------ -----------------------
  **Baseline AHI**                                                                                                                                          
  Mild \[[@R35]\]                                                 1                   −2.01 (−2.70, −1.32)                      \<0.001              42%    0.142
  Moderate \[[@R24]--[@R26],[@R33],[@R48]\]                       5                   −1.38 (−2.48, −0.27)                      0.15                 73%    0.025
  Severe \[[@R34],[@R49],[@R51]\]                                 3                   −2.68 (−5.89, 0.54)                       0.103                48%    0.051
  **Baseline ESS**                                                                                                                                          
  Moderate \[[@R24]--[@R26],[@R35],[@R49],[@R51]\]                6                   −1.36 (−2.07, −0.64)                      \<0.001              --     --
  Severe \[[@R34]\]                                               1                   −8.50 (−13.64, −3.36)                     0.001                55%    0.037
  **Trial design**                                                                                                                                          
  Crossover \[[@R24],[@R35],[@R48],[@R49]\]                       4                   −1.75 (−2.25, −1.25)                      \<0.001              2%     0.380
  Parallel \[[@R25],[@R26],[@R33],[@R34],[@R51]\]                 5                   −2.18 (−4.80, 0.44)                       0.102                68%    0.015
  **Duration of treatment**                                                                                                                                 
  2--12 wk \[[@R24],[@R25],[@R33],[@R35],[@R48],[@R49],[@R51]\]   7                   −1.75 (−2.22, −1.28)                      \<0.001              0%     0.521
  \<12 wk \[[@R26],[@R34]\]                                       2                   −3.26 (−13.15, 6.63)                      0.518                90%    0.001
  **Overall MAD compared with controls**                                                                                                                    
  Overall                                                         9                   −1.64 (−2.46, −0.82)                      \<0.001              48%    0.051

Mean baseline AHI (or DI if AHI not reported) events/hour: mild (AHI 5--14, DI 5--9), moderate (AHI 15--30, DI 10--30) and severe (AHI \> 30, DI \> 30).

Mean baseline ESS score: normal/mild (0--9), moderate (10--15) and severe (16--24).

Abbreviations: AHI: apnoea-hypopnoea index; CI: confidence interval; DI: desaturation index; ESS: Epworth Sleepiness Scale; I^2^ proportion of total variability explained by heterogeneity; MAD: mandibular advancement device.

###### 

Subgroup analysis of ESS results for comparison of MAD against CPAP (positive estimates favour CPAP).

  Subgroup                                                          Number of studies   Difference in ESS: MAD-CPAP (95%CI)   P value for effect   I^2^   Heterogeneity P value
  ----------------------------------------------------------------- ------------------- ------------------------------------- -------------------- ------ -----------------------
  **Baseline AHI**                                                                                                                                        
  Moderate \[[@R24]--[@R26],[@R28],[@R36],[@R54]\]                  6                   0.06 (−0.61, 0.72)                    0.864                0%     0.659
  Severe \[[@R31],[@R46],[@R52],[@R53]\]                            4                   1.42 (−0.24, 3.08)                    0.094                68%    0.024
  **Baseline ESS**                                                                                                                                        
  Moderate \[[@R24]--[@R26],[@R31],[@R36],[@R46],[@R52]--[@R54]\]   9                   0.81 (−0.04, 1.65)                    0.062                49%    0.049
  **Trial design**                                                                                                                                        
  Crossover \[[@R24],[@R28],[@R36],[@R46],[@R53],[@R54]\]           6                   0.54 (−0.48, 1.57)                    0.301                60%    0.030
  Parallel \[[@R25],[@R26],[@R31],[@R52]\]                          4                   0.97 (−0.16, 2.11)                    0.093                0%     0.399
  **Duration of treatment**                                                                                                                               
  2--12 wk \[[@R24],[@R25],[@R31],[@R36],[@R46],[@R52]--[@R54]\]    8                   0.82 (−0.09, 1.73)                    0.078                55%    0.031
  \> 12 wk \[[@R26],[@R28]\]                                        2                   −0.06 (--1.66, 1.54)                  0.944                0%     0.461
  **Overall MAD compared with CPAP**                                                                                                                      
  Overall                                                           10                  0.67 (−0.11, 1.44)                    0.093                45%    0.059

Mean baseline AHI (or DI if AHI not reported) events/hour: mild (AHI 5--14, DI 5--9), moderate (AHI 15--30, DI 10--30) and severe (AHI \> 30, DI \> 30).

Mean baseline ESS score: normal/mild (0--9) moderate (10--15) and severe (16--24).

Abbreviations: AHI: apnoea-hypopnoea index; CI: confidence interval; CPAP: continuous positive airway pressure; DI: desaturation index; ESS: Epworth sleepiness scale; I^2^: proportion of total variability explained by heterogeneity; MAD: mandibular advancement device.

###### 

Subgroup analysis of ESS results for comparison of CPAP against conservative management (negative estimates favour CPAP).

  Subgroup                                                                                                                                                                             Number of studies   Difference in ESS: CPAP-control (95%CI)   P value for effect   I^2^   Heterogeneity P value
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------- ----------------------------------------- -------------------- ------ -----------------------
  **Baseline AHI**                                                                                                                                                                                                                                                               
  Mild \[[@R32],[@R60],[@R65],[@R71],[@R73]\]                                                                                                                                          5                   −1.23 (−2.19, −0.27)                      0.012                59%    0.045
  Moderate \[[@R24]--[@R26],[@R79],[@R84]--[@R86],[@R90],[@R91],[@R95]\]                                                                                                               10                  −1.82 (--2.73, --0.92)                    \<0.001              60%    0.008
  Severe \[[@R14],[@R16],[@R32],[@R57]--[@R65],[@R68],[@R69],[@R71]--[@R74],[@R76]--[@R78],[@R81],[@R83],[@R87],[@R89],[@R92],[@R97]\]                                                 22                  −2.64 (--3.44, --1.84)                    \<0.001              86%    \<0.001
  **Baseline ESS**                                                                                                                                                                                                                                                               
  Normal/Mild \[[@R58],[@R59],[@R65],[@R83],[@R91]                                                                                                                                     5                   −0.83 (−1.16, −0.51)                      \<0.001              30%    0.222
  Moderate \[[@R14],[@R24]--[@R26],[@R32],[@R57],[@R60]--[@R62],[@R64],[@R68],[@R69],[@R71]--[@R74],[@R77],[@R78],[@R81],[@R84]--[@R86],[@R89],[@R90],[@R92],[@R95],[@R97],[@R100]\]   28                  −2.19 (−2.84, −1.53)                      \<0.001              76%    \<0.001
  Severe \[[@R16],[@R63],[@R76],[@R79],[@R87]\]                                                                                                                                        5                   −4.99 (−6.51, −3.47)                      \<0.001              46%    0.115
  **Trial design**                                                                                                                                                                                                                                                               
  Crossover \[[@R24],[@R60],[@R64],[@R71]--[@R74],[@R85],[@R89],[@R91],[@R92],[@R95]\];                                                                                                12                  −2.32 (−3.33, −1.31)                      \<0.001              79%    \<0.001
  Parallel \[[@R14],[@R16],[@R25],[@R26],[@R32],[@R57]--[@R59],[@R61]--[@R63],[@R65],[@R68],[@R69],[@R76]--[@R79][@R81],[@R83],[@R84],[@R86],[@R87],[@R90],[@R97],[@R100]\]            26                  −2.15 (−2.74, −1.55)                      \<0.001              82%    \<0.001
  **Duration of treatment**                                                                                                                                                                                                                                                      
  2--4 wk \[[@R14],[@R16],[@R62],[@R71]--[@R74],[@R76],[@R79],[@R85],[@R91],[@R95],[@R97]\]                                                                                            13                  −2.58 (−3.66, −1.51)                      \<0.001              75%    \<0.001
  5--12 wk \[[@R24],[@R25],[@R32],[@R57],[@R58],[@R60],[@R61],[@R63],[@R64],[@R69],[@R77],[@R78],[@R84],[@R87],[@R89],[@R90],[@R100]\]                                                 17                  −2.20 (−3.02, −1.39)                      \<0.001              68%    \<0.001
  \>12 wk \[[@R26],[@R59],[@R65],[@R68],[@R81],[@R83],[@R86],[@R92]\]                                                                                                                  8                   −1.87 (−2.83, −0.90)                      \<0.001              93%    \<0.001
  **Overall CPAP compared with controls**                                                                                                                                                                                                                                        
  Overall                                                                                                                                                                              38                  −2.23 (−2.76, −1.71)                      \<0.001              83%    \<0.001

Mean baseline AHI (or DI if AHI not reported) events/hour: mild (AHI 5--14, DI 5--9), moderate (AHI 15--30, DI 10--30) and severe (AHI \> 30, DI \> 30).

Mean baseline ESS score: normal/mild (0--9), moderate (10--15) and severe (16--24).

Abbreviations: AHI: apnoea-hypopnoea index; CI: confidence interval; CPAP: continuous positive airway pressure; DI: desaturation index; ESS: Epworth sleepiness scale; I^2^: proportion of total variability explained by heterogeneity; MAD: mandibular advancement device.
